BRPI0413728A - muteìnas de lipocalina da lágrima - Google Patents

muteìnas de lipocalina da lágrima

Info

Publication number
BRPI0413728A
BRPI0413728A BRPI0413728-0A BRPI0413728A BRPI0413728A BR PI0413728 A BRPI0413728 A BR PI0413728A BR PI0413728 A BRPI0413728 A BR PI0413728A BR PI0413728 A BRPI0413728 A BR PI0413728A
Authority
BR
Brazil
Prior art keywords
mutein
tear lipocalin
lipocalin muteins
lipocalin
relates
Prior art date
Application number
BRPI0413728-0A
Other languages
English (en)
Inventor
Arne Skerra
Steffen Schlehuber
Original Assignee
Pieris Proteolab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Proteolab Ag filed Critical Pieris Proteolab Ag
Publication of BRPI0413728A publication Critical patent/BRPI0413728A/pt
Publication of BRPI0413728B1 publication Critical patent/BRPI0413728B1/pt
Publication of BRPI0413728B8 publication Critical patent/BRPI0413728B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MUTEìNAS DE LIPOCALINA DA LáGRIMA". A presente invenção refere-se às novas muteínas derivadas de lipocalina da lágrima ou um homólogo da mesma. Especificamente, a invenção refere-se a uma muteína da lágrima humana. A invenção também se refere a uma molécula de ácido nucléico correspondente codificando tal muteína e a um processo para sua geração. A invenção se refere, adicionalmente, a um método para produzir tal muteína. Finalmente, a invenção é dirigida a uma composição farmacêutica compreendendo tal muteína de lipocalina, bem como aos vários usos da muteína.
BRPI0413728A 2003-08-25 2004-08-24 muteína da lipocalina da lágrima humana, métodos para geração e para produção de muteína, composição farmacêutica e uso de muteína BRPI0413728B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2003/009404 WO2005019255A1 (en) 2003-08-25 2003-08-25 Muteins of tear lipocalin
PCT/EP2004/009447 WO2005019256A2 (en) 2003-08-25 2004-08-24 Muteins of tear lipocalin

Publications (3)

Publication Number Publication Date
BRPI0413728A true BRPI0413728A (pt) 2006-10-24
BRPI0413728B1 BRPI0413728B1 (pt) 2017-05-23
BRPI0413728B8 BRPI0413728B8 (pt) 2021-05-25

Family

ID=34203142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413728A BRPI0413728B8 (pt) 2003-08-25 2004-08-24 muteína da lipocalina da lágrima humana, métodos para geração e para produção de muteína, composição farmacêutica e uso de muteína

Country Status (13)

Country Link
US (2) US7585940B2 (pt)
EP (1) EP1660528B1 (pt)
JP (1) JP4856543B2 (pt)
CN (1) CN1871256B (pt)
AT (1) ATE446313T1 (pt)
AU (2) AU2003275958A1 (pt)
BR (1) BRPI0413728B8 (pt)
CA (1) CA2536491C (pt)
DE (1) DE602004023725D1 (pt)
DK (1) DK1660528T3 (pt)
HK (1) HK1084404A1 (pt)
SG (1) SG131109A1 (pt)
WO (2) WO2005019255A1 (pt)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019255A1 (en) * 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
US7611847B2 (en) 2005-06-01 2009-11-03 Agency For Science, Technology And Research Method for identifying an intestinal phenotype
CN101371124B (zh) 2006-02-13 2012-02-29 新加坡科技研究局 处理生物样品和/或化学样品的方法
EP2004328B1 (en) 2006-03-09 2014-06-04 Agency for Science, Technology and Research Method for performing a reaction in a droplet
US8598317B2 (en) 2006-03-20 2013-12-03 Technische Universitaet Muenchen Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4
ES2354653T3 (es) * 2006-08-01 2011-03-16 Pieris Ag Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas.
EP2046820B1 (en) * 2006-08-01 2010-10-20 Pieris AG Muteins of tear lipocalin and methods for obtaining the same
US9874501B2 (en) 2006-11-24 2018-01-23 Curiox Biosystems Pte Ltd. Use of chemically patterned substrate for liquid handling, chemical and biological reactions
WO2008063135A1 (en) 2006-11-24 2008-05-29 Agency For Science, Technology And Research Apparatus for processing a sample in a liquid droplet and method of using the same
WO2008127199A1 (en) 2007-04-13 2008-10-23 Agency For Science, Technology And Research Methods of controlling tumorigenesis and diagnosing the risk thereof
WO2009058102A1 (en) 2007-11-02 2009-05-07 Agency For Science, Technology And Research Methods and compounds for preventing and treating a tumour
WO2013114217A1 (en) 2012-02-05 2013-08-08 Curiox Biosystems Pte Ltd. Array plates and methods for making and using same
US10725020B2 (en) 2007-11-14 2020-07-28 Curiox Biosystems Pte Ltd. High throughput miniaturized assay system and methods
EP2641919A3 (en) 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
US9212208B2 (en) * 2008-01-30 2015-12-15 Pieris Ag Muteins with tear lipocalin having affinity to human c-Met receptor tyrosine kinase and methods for obtaining the same
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase
US9051568B2 (en) 2008-04-25 2015-06-09 Rutgers, The State University Of New Jersey Anti-sense microrna expression vectors
JP2011522792A (ja) 2008-05-06 2011-08-04 グラクソ グループ リミテッド 生物活性薬の封入
WO2009136867A1 (en) 2008-05-06 2009-11-12 Agency For Science, Technology And Research Method of effecting de-differentiation of a cell
EP3381933B1 (en) 2008-06-24 2020-06-03 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
JP2010074915A (ja) * 2008-09-17 2010-04-02 Jtekt Corp モータ制御装置及び電動パワーステアリング装置
US8716420B2 (en) 2008-10-13 2014-05-06 Agency For Science, Technology And Research Amphiphilic polymers and nanocrystals coated therewith
EP2189539B2 (en) 2008-11-21 2018-06-13 Chimera Biotec GmbH Conjugate complexes for analyte detection
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
EP2401296A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
EP2401298A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
CA2753332A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US8784752B2 (en) 2009-04-17 2014-07-22 Curiox Biosystems Pte Ltd Use of chemically patterned substrate for liquid handling, chemical and biological reactions
WO2011005221A1 (en) 2009-07-07 2011-01-13 Agency For Science, Technology And Research Methods of identifying a pair of binding partners
CN102548466A (zh) 2009-07-28 2012-07-04 霍夫曼-拉罗奇有限公司 非侵入性体内光学成像方法
CN106139123A (zh) * 2009-08-05 2016-11-23 爱力根公司 脂质运载蛋白突变蛋白的控制释放制剂
CA2779562C (en) 2009-12-07 2019-12-31 Pieris Ag Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
WO2011078794A1 (en) 2009-12-22 2011-06-30 Agency For Science, Technology And Research Sers-based analyte detection
PE20121702A1 (es) 2010-01-28 2012-12-14 Glaxo Group Ltd Proteinas de enlace cd127
KR101341640B1 (ko) * 2010-02-05 2013-12-16 한국전자통신연구원 단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
EP3153521B1 (en) 2010-03-26 2019-09-04 Trustees of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
RU2012148816A (ru) 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
EP2580236B1 (en) 2010-06-08 2019-04-03 Pieris Pharmaceuticals GmbH Tear lipocalin muteins binding il-4 r alpha
WO2012011877A2 (en) 2010-07-23 2012-01-26 Curiox Biosystems Pte Ltd Apparatus and method for multiple reactions in small volumes
CN103154023B (zh) 2010-08-16 2017-04-05 皮里斯制药有限公司 铁调素的结合蛋白
WO2012032069A1 (en) 2010-09-07 2012-03-15 Pieris Ag Recombinant bacterial lipocalin blc and uses thereof
EP2614086A1 (en) * 2010-09-08 2013-07-17 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
DK2640740T3 (en) * 2010-11-15 2017-06-26 Pieris Pharmaceuticals Gmbh MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
JP6351973B2 (ja) 2010-11-23 2018-07-04 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合タンパク質
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
WO2012136685A1 (en) 2011-04-04 2012-10-11 Pieris Ag Methods and compositions for anti-vegf and anti-c-met therapy
RU2016147206A (ru) 2011-04-15 2018-10-19 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
EA201790330A1 (ru) 2011-05-27 2018-02-28 Глаксо Груп Лимитед Белки, связывающиеся с bcma (cd269/tnfrsf17)
WO2013048986A1 (en) 2011-09-26 2013-04-04 Knoa Software, Inc. Method, system and program product for allocation and/or prioritization of electronic resources
WO2013059886A1 (en) 2011-10-28 2013-05-02 Patrys Limited Pat-lm1 epitopes and methods for using same
SG10201604574UA (en) 2011-12-12 2016-07-28 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
US9572863B2 (en) 2011-12-13 2017-02-21 Pieris Pharmaceuticals Gmbh Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
ES2749620T3 (es) 2011-12-30 2020-03-23 Halozyme Inc Variantes de polipéptidos de PH20, formulaciones y usos de los mismos
CA2860843C (en) 2012-01-09 2021-03-23 Pieris Ag Methods for preventing, treating or diagnosing disorders
WO2013113851A1 (en) 2012-01-31 2013-08-08 Technische Universitaet Muenchen Muteins of a1m lipocalin and method of production therefor
JP6383665B2 (ja) 2012-02-13 2018-08-29 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ＩＬ‐１β中和ヒトモノクローナル抗体
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
WO2013189521A1 (en) 2012-06-19 2013-12-27 Waclawczyk Simon Method of generating cells of hepatocyte phenotype
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
EP3552628A1 (en) 2012-09-07 2019-10-16 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
CA2884431A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
BR112015021681A2 (pt) 2013-03-14 2017-11-14 Daiichi Sankyo Co Ltd proteínas de ligação para pcsk9
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
US9557318B2 (en) 2013-07-09 2017-01-31 Curiox Biosystems Pte Ltd. Array plates for washing samples
WO2015051199A2 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
PL3074038T3 (pl) 2013-11-28 2019-08-30 Csl Limited Sposób leczenia nefropatii cukrzycowej
AU2014366837B2 (en) 2013-12-18 2020-06-25 B-Creative Sweden Ab Method of treating wounds
EP3712174B1 (en) 2013-12-24 2022-03-16 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US10927154B2 (en) 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
LU92409B1 (en) 2014-03-21 2015-09-22 Philipps Universit T Marburg Means and methods for itaconic acid production
RU2723034C2 (ru) * 2014-05-22 2020-06-08 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые полипептиды со специфическим связыванием и пути их применения
US11123426B2 (en) 2014-06-11 2021-09-21 The Trustees Of Dartmouth College Use of vista agonists and antagonists to suppress or enhance humoral immunity
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
HUE054122T2 (hu) 2014-11-14 2021-08-30 Hoffmann La Roche TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
US11382963B2 (en) 2015-01-12 2022-07-12 Pieris Pharmaceuticals Gmbh Engineered T cells and uses therefor
BR112017015773A2 (pt) 2015-01-28 2018-03-27 Pieris Pharmaceuticals Gmbh muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
CN107820500B (zh) * 2015-05-04 2022-03-01 皮里斯制药有限公司 Cd137特异性的蛋白
EP3292148B1 (en) 2015-05-04 2024-01-24 Pieris Pharmaceuticals GmbH Anti-cancer fusion polypeptide
ES2938525T3 (es) 2015-05-18 2023-04-12 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anticanceroso
RU2756318C2 (ru) 2015-05-18 2021-09-29 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3)
US10545139B2 (en) 2015-06-16 2020-01-28 Curiox Biosystems Pte Ltd. Methods and devices for performing biological assays using magnetic components
CN114805576A (zh) 2015-06-24 2022-07-29 詹森药业有限公司 抗vista抗体和片段
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
EA201890198A1 (ru) * 2015-07-15 2018-07-31 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые белки, специфичные в отношении lag-3
EP3331901A1 (en) 2015-08-07 2018-06-13 Pieris Pharmaceuticals GmbH Novel fusion polypeptide specific for lag-3 and pd-1
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CR20180161A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Anticuerpos biespecíficos para pd1 y tim3
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
MY193013A (en) 2015-10-07 2022-09-22 Hoffmann La Roche Bispecific antibodies with tetravalency for a costimulatory tnf receptor
JP2019505565A (ja) 2015-11-30 2019-02-28 ピエリス オーストラリア プロプライエタリー リミテッド 新規の抗血管新生融合ポリペプチド
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
AU2017250294B2 (en) 2016-04-15 2022-07-21 Immunext Inc. Anti-human VISTA antibodies and use thereof
EP3455254B1 (en) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
WO2018050902A2 (en) 2016-09-15 2018-03-22 Quadrucept Bio Limited Multimers, tetramers & octamers
CN110023339A (zh) 2016-09-23 2019-07-16 Csl有限公司 凝血因子结合蛋白及其应用
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN110087682B (zh) 2016-12-19 2023-12-15 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
PL3559034T3 (pl) 2016-12-20 2021-04-19 F. Hoffmann-La Roche Ag Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
MX2019007795A (es) 2017-01-03 2019-08-16 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.
EP3571219A1 (en) 2017-01-18 2019-11-27 Pieris Pharmaceuticals GmbH Lipocalin muteins with binding affinity for lag-3
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
CR20190427A (es) 2017-04-04 2019-11-01 Hoffmann La Roche Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap
CN110506059B (zh) 2017-04-05 2023-01-17 豪夫迈·罗氏有限公司 特异性结合pd1和lag3的双特异性抗体
EP3607580B1 (en) 2017-04-05 2023-05-31 Curiox Biosystems Pte Ltd. Methods, devices, and apparatus for washing samples on array plates
US11466073B2 (en) 2017-10-18 2022-10-11 Csl Limited Human serum albumin variants and uses thereof
EP3704155A2 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Combination therapy with targeted ox40 agonists
US20210324108A1 (en) 2017-11-01 2021-10-21 Hoffmann-La Roche Inc. Bispecific 2+1 contorsbodies
EP3703746A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Novel tnf family ligand trimer-containing antigen binding molecules
DK3717011T3 (da) 2017-11-29 2023-01-09 Csl Ltd Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CN111683961A (zh) 2018-03-13 2020-09-18 豪夫迈·罗氏有限公司 4-1bb激动剂与抗cd20抗体的治疗剂组合
BR112020013425A2 (pt) 2018-03-13 2020-12-01 F. Hoffmann-La Roche Ag agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e um agente de direcionamento de her-2 e método para tratar ou retardar a progressão do câncer em um indivíduo
AR114284A1 (es) 2018-04-13 2020-08-12 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
WO2019243564A1 (en) 2018-06-21 2019-12-26 Technische Universitaet Muenchen Hepatitis b and/or hepatitis d-permissive cells and animals
JP2021528988A (ja) 2018-07-04 2021-10-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
RS64343B9 (sr) 2018-07-31 2023-11-30 Pieris Pharmaceuticals Gmbh Novi fuzioni protein specifičan za cd137 i pd-l1
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
CA3113548A1 (en) 2018-10-01 2020-04-09 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-fap clone 212
TW202030204A (zh) 2018-12-21 2020-08-16 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之超促效cd28抗原結合分子
MA54513A (fr) 2018-12-21 2022-03-30 Hoffmann La Roche Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
MA55069A (fr) 2019-02-26 2022-01-05 Pieris Pharmaceuticals Gmbh Nouvelles protéines de fusion spécifique à cd137 et gpc3
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP3946417A1 (en) 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhaled administration of lipocalin muteins
CN113613669A (zh) 2019-03-29 2021-11-05 阿斯利康有限公司 用于治疗哮喘的脂质运载蛋白突变蛋白
JP7301155B2 (ja) 2019-04-12 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト リポカリンムテインを含む二重特異性抗原結合分子
JP2022538075A (ja) 2019-06-26 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体結合ｃｅａ及び４－１ｂｂｌの融合
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
EP4054718A1 (en) 2019-11-04 2022-09-14 Pieris Pharmaceuticals GmbH Her2/4-1bb bispecific fusion proteins for the treatment of cancer
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
KR20230020443A (ko) 2020-06-05 2023-02-10 피어이스 파마슈티컬즈 게엠베하 4-1bb 표적화 다량체 면역조절제
IL297880A (en) 2020-06-23 2023-01-01 Hoffmann La Roche Agonistic cd28 antigen-binding molecules targeting her2
JP2023531067A (ja) 2020-06-25 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
JP2023549316A (ja) 2020-11-16 2023-11-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法
WO2022129629A1 (en) 2020-12-18 2022-06-23 Astrazeneca Ab Lipocalin mutein dry powder formulation for treatment of asthma
KR20230117406A (ko) 2021-01-06 2023-08-08 에프. 호프만-라 로슈 아게 Pd1-lag3 이중특이성 항체와 cd20 t 세포 이중특이성항체를 이용한 조합 요법
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022200412A2 (en) 2021-03-23 2022-09-29 Pieris Pharmaceuticals Gmbh Her2/4-1bb bispecific fusion proteins for the treatment of cancer
JP2024515564A (ja) 2021-04-08 2024-04-10 ピエリス ファーマシューティカルズ ゲーエムベーハー 結合組織増殖因子（ｃｔｇｆ）に特異的な新規リポカリンムテイン
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
AU2022302170A1 (en) 2021-07-02 2023-12-21 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023089079A1 (en) 2021-11-19 2023-05-25 Pieris Pharmaceuticals Gmbh Novel fusion protein specific for ox40 and pd-l1
AR128031A1 (es) 2021-12-20 2024-03-20 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024064713A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2152818A1 (en) 1992-12-31 1994-07-21 Jay P. Morgenstern Allergenic proteins and peptides from dog dander and uses therefor
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2002255478A1 (en) * 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20030236188A1 (en) 2001-05-03 2003-12-25 Spytek Kimberly A. Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2005019255A1 (en) * 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin

Also Published As

Publication number Publication date
EP1660528B1 (en) 2009-10-21
US20090325875A1 (en) 2009-12-31
DK1660528T3 (da) 2010-01-04
JP4856543B2 (ja) 2012-01-18
WO2005019255A8 (en) 2005-05-26
EP1660528A2 (en) 2006-05-31
CA2536491C (en) 2013-12-24
JP2007531503A (ja) 2007-11-08
AU2004266846A1 (en) 2005-03-03
WO2005019256A2 (en) 2005-03-03
US20070224633A1 (en) 2007-09-27
WO2005019255A1 (en) 2005-03-03
CA2536491A1 (en) 2005-03-03
HK1084404A1 (en) 2006-07-28
AU2004266846B2 (en) 2011-01-06
US7585940B2 (en) 2009-09-08
BRPI0413728B8 (pt) 2021-05-25
DE602004023725D1 (de) 2009-12-03
AU2003275958A1 (en) 2005-03-10
BRPI0413728B1 (pt) 2017-05-23
SG131109A1 (en) 2007-04-26
ATE446313T1 (de) 2009-11-15
WO2005019256A3 (en) 2005-07-21
US7893208B2 (en) 2011-02-22
CN1871256B (zh) 2010-06-23
CN1871256A (zh) 2006-11-29

Similar Documents

Publication Publication Date Title
BRPI0413728A (pt) muteìnas de lipocalina da lágrima
MX2009001203A (es) Muteinas de lipocalina lacrimosa y metodos para obtener las mismas.
HUP0500634A2 (hu) Anyagok és eljárások az idegszövet helyreállításának elősegítésére
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
DK0910647T3 (da) Human DNase i hyperaktive varianter
ATE370968T1 (de) Varianten des menschliche koagulationsfaktors vii
DE60224928D1 (de) Dermatologische und kosmetische zusammensetzungen enthaltend ein furfurylderivat
PT1411908E (pt) Tratamento de infeccoes da unha com no
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
NO20031129D0 (no) Varianter av human koagulasjonsfaktor VII
SE0301653D0 (sv) Novel compounds
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
NO20050247L (no) Lavmolekylaert oversulfatert polysakkarid
BR0311568A (pt) Método de tratamento de cabelo e uso de uma composição
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
WO2005016371A8 (en) IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES
DE60104866D1 (de) Aminoalkenylbenzoyl-benzofurane oder benzothiophene, verfahren zur ihrer herstellung und sie enthaltende zubereitungen
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
WO2005034978A3 (en) MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF
ATE480522T1 (de) 9-alkylamino-1-nitroacridin-derivate
WO2004071383A3 (en) New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
WO2005023767A3 (en) Diastereomers of 4-aryloxy-3-hydroxypiperidines

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF